NCT03010527 - A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

217

Participants

Timeline

Start Date

December 14, 2016

Primary Completion Date

September 25, 2018

Study Completion Date

September 25, 2018

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG

Bimekizumab

Subjects will receive bimekizumab injections every four weeks (Q4W)

OTHER

Placebo

Subjects will receive Placebo injections every four weeks (Q4W)

Trial Locations (36)

20037

Ps0011 706, Washington D.C.

28405

Ps0011 738, Wilmington

50265

Ps0011 704, West Des Moines

75231

Ps0011 733, Dallas

77004

Ps0011 709, Houston

77598

Ps0011 702, Houston

90045

Ps0011 708, Los Angeles

97223

Ps0011 712, Portland

Unknown

Ps0011 209, Edmonton

Ps0011 201, North Bay

Ps0011 206, Peterborough

Ps0011 214, Québec

Ps0011 203, Surrey

Ps0011 205, Waterloo

Ps0011 300, Ostrava

Ps0011 303, Pardubice

Ps0011 301, Prague

Ps0011 304, Prague

Ps0011 404, Kecskemét

Ps0011 400, Orosháza

Ps0011 405, Szekszárd

Ps0011 504, Chiyoda-ku

Ps0011 503, Minatoku

Ps0011 502, Nagoya

Ps0011 501, Shinagawa-ku

Ps0011 600, Bialystok

Ps0011 603, Bialystok

Ps0011 611, Bialystok

Ps0011 610, Gdynia

Ps0011 604, Kielce

Ps0011 608, Krakow

Ps0011 605, Lublin

Ps0011 606, Lublin

Ps0011 607, Warsaw

Ps0011 601, Wroclaw

Ps0011 609, Wroclaw

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY